Ultragenyx Pharmaceutical Inc.
RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypopā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$21.34
Price-1.71%
-$0.37
1Y
Price
Market Cap
$2.062b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-50.8%
EBITDA Margin-62.3%
Net Profit Margin-48.7%
Free Cash Flow Margin-50.8%
EBITDA Margin-62.3%
Net Profit Margin-48.7%
Free Cash Flow MarginRevenue
$673m
+20.1%
1y CAGR+22.9%
3y CAGR+18.0%
5y CAGREarnings
-$575m
-1.1%
1y CAGR+6.4%
3y CAGR-9.1%
5y CAGREPS
-$5.83
+7.2%
1y CAGR+16.5%
3y CAGR-0.4%
5y CAGRBook Value
-$73m
$1.532b
Assets$1.605b
Liabilities$1.276b
DebtDebt to Assets
83.3%
-2.7x
Debt to EBITDAFree Cash Flow
-$472m
-11.9%
1y CAGR+2.7%
3y CAGR-4.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company